Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Glofitamab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Glofitamab as a study intervention. Browse Glofitamab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
39
Shown on this page
3
Current sort
Recently updated
Therapy scope
Glofitamab
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Glofitamab. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 37–39 of 39 matching trials for Glofitamab.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Withdrawn Phase 2 Interventional

A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma

NCT06670105
View directory record Official record
Conditions
B-cell Lymphoma
Interventions
Glofitamab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 17, 2026, 1:00 AM EDT
Completed Phase 1 Interventional

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

NCT03467373
View directory record Official record
Conditions
B-Cell Lymphoma, Non-Hodgkin Lymphoma
Interventions
Glofitamab, Obinutuzumab (G), Rituximab (R), Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 17, 2026, 1:00 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT05219513
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
RO7443904, Glofitamab, Obinutuzumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 17, 2026, 1:00 AM EDT

About this Glofitamab clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Glofitamab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Glofitamab.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Glofitamab.